Evidence map›Paper›PMID 39356143›Full record

ArticleCancer research communications2024

USP36 SUMOylates Las1L and Promotes Its Function in Pre-Ribosomal RNA ITS2 Processing.

Yanping Li, Yunhan Yang, Rosalie C Sears, Mu-Shui Dai, Xiao-Xin Sun

Abstract read
In one paragraph

Article in Cancer research communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. A NovelGenes · 2026
    Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yanping LiDepartment of Molecular and Medical Genetics, School of Medicine, and the OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0002-9857-9019
Yunhan YangDepartment of Molecular and Medical Genetics, School of Medicine, and the OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0001-8143-5919
Rosalie C SearsDepartment of Molecular and Medical Genetics, School of Medicine, and the OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0003-1558-2413
Mu-Shui DaiDepartment of Molecular and Medical Genetics, School of Medicine, and the OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0001-9031-6962
Xiao-Xin SunDepartment of Molecular and Medical Genetics, School of Medicine, and the OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0002-4607-6604

Funding

Hydroxylation regulation of c-MycR01CA186241 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Mu-Shui Dai, ROSALIE C SEARS · 2015 to 2026
$4.2M
Regulation of the nucleolar RNA exosome in cancerR01CA262104 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Mu-Shui Dai · 2022 to 2026
$2.3M
Novel roles for USP36 in ribosome biogenesisR01GM130604 · NIGMS · OREGON HEALTH & SCIENCE UNIVERSITY · PI DAI, MU-SHUI · 2019 to 2022
$1.2M
SUMOylation regulation of ribosome biogenesisR35GM153360 · NIGMS · OREGON HEALTH & SCIENCE UNIVERSITY · PI Mu-Shui Dai · 2024 to 2026
$1.2M
NCI NIH HHS R01 CA186241NCI NIH HHS R01 CA262104NIGMS NIH HHS R01 GM130604NIGMS NIH HHS R35 GM153360
6 · The paper itself

Abstract

Ribosome biogenesis is a highly regulated cellular process requiring a large cohort of accessory factors to ensure the accurate production of ribosomes. Dysregulation of ribosome biogenesis is associated with the development of various human diseases, including cancer. The Las1L-Nol9 endonuclease-kinase complex is essential for the cleavage of the rRNA internal transcribed spacer 2 (ITS2), the phosphorylation of the 5'-hydroxyl end of the resulting precursor, and, thus, the maturation of the 60S ribosome. However, how the Las1L-Nol9 complex is regulated in cells is unclear. In this study, we report that the nucleolar ubiquitin-specific protease USP36 is a novel regulator of the Las1L-Nol9 complex. USP36 interacts with both Las1L and Nol9 and regulates their stability via deubiquitination. Intriguingly, USP36 also mediates the SUMOylation of Las1L, mainly at lysine (K) 565. Mutating K565 to arginine (R) does not affect the levels of Las1L and the formation of the Las1L-Nol9 complex, but abolishes its function in ITS2 processing, as unlike wild-type Las1L, the K565R mutant failed to rescue the defects in the ITS2 processing induced by the knockdown of endogenous Las1L. These results suggest that USP36-mediated Las1L SUMOylation is critical for ITS2 processing and that USP36 plays a critical role in ribosome biogenesis by regulating the Las1L-Nol9 complex. SIGNIFICANCE: This study identifies USP36 as a deubiquitinating and small ubiquitin-like modifier ligase dual-function enzyme to mediate Las1L deubiquitination and SUMOylation. Las1L SUMOylation at K565 plays a critical role in pre-rRNA ITS2 processing. Thus, our study reveals a novel downstream pathway for USP36-regulated ribosome biogenesis.

Indexed as

RNA PrecursorsSumoylationUbiquitin ThiolesteraseEndonucleasesHEK293 CellsHeLa CellsHumansNuclear ProteinsRibosomesRNA Processing, Post-TranscriptionalRNA, RibosomalUbiquitinationEndonucleasesLas1L protein, humanNuclear ProteinsRNA PrecursorsRNA, RibosomalUbiquitin ThiolesteraseUSP36 protein, human

Identifiers

PMID39356143
PMCPMC11523043

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.